Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Over the last decade, a vast panorama of evidence on the benefit–risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM). In this a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Eur Endocrinol
Главные авторы: Mathieu, Chantal, Kozlovski, Plamen, Paldánius, Päivi M, Foley, James E, Modgill, Vikas, Evans, Marc, Serban, Carmen
Формат: Artigo
Язык:Inglês
Опубликовано: Touch Medical Media 2017
Предметы:
Type 2 Diabetes
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813467/
https://ncbi.nlm.nih.gov/pubmed/29632610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.68
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы